Viatris’ Mylan and Fujifilm Kyowa Kirin Biologics have launched Japan’s first biosimilar rival to AbbVie’s Humira (adalimumab). The launch follows the product’s approval at the end of June last year. (Also see "Japan Approves First Humira Biosimilar" - Generics Bulletin, 30 June, 2020.)
Having previously launched the product under the name Hulio in Europe – under a partnership struck in 2018 that was later expanded globally in 2019 – the firms also received US Food and Drug Administration approval for Hulio midway through last year. (Also see "FDA Approves Mylan’s Humira Biosimilar" - Generics Bulletin, 8 July, 2020
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?